PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Jackson, Evangeline R., Kearney, Padraic S., Jamaluddin, M. Fairuz B., Douglas, Alicia M., Beitaki, Tyrone, McEwen, Holly P., Persson, Mika L., Hocke, Emily A., Jain, Vaibhav, Aksu, Michael, Manning, Elizabeth E., Parackal, Sarah G., Murray, Heather C., Verrills, Nicole M., Hua, Susan, Cairns, Murray J., Alvaro, Frank, Dayas, Christopher V., Dun, Matthew D., Hua, S, de Bock, CE, Colino-Sanguino, Y, Kiltschewskij, Dylan, Valdes-Mora, F, Tsoli, M, Ziegler, DS, Cairns, MJ, Raabe, EH, Vitanza, NA, Hulleman, E, Phoenix, TN, Koschmann, C, Alvaro, F, Findlay, Izac J., Dayas, CV, Tinkle, CL, Wheeler, H, Whittle, JR, Eisenstat, DD, Firestein, R, Mueller, S, Valvi, S, Hansford, JR, Ashley, DM, Mannan, Abdul, Gregory, SG, Kilburn, LB, Nazarian, J, Cain, JE, Dun, MD, Staudt, Dilana E., Thomas, Bryce C., Germon, Zacary P., Laternser, Sandra

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

- Jackson, Evangeline R., Duchatel, Ryan J., Le Grand, Marion, Kearney, Padraic S., Douglas, Alicia M., Findlay, Izac J., Germon, Zacary P., McEwen, Holly P., Beitaki, Tyrone S., Patabendige, Adjanie, Skerrett-Byrne, David A., Nixon, Brett, Staudt, Dilana E., Smith, Nathan D., Day, B, Manoharan, N, Nagabushan, S, Hansford, JR, Govender, D, McCowage, GB, Firestein, R, Howlett, M, Endersby, R, Persson, Mika L., Gottardo, NG, Alvaro, F, Waszak, SM, Larsen, MR, Colino-Sanguino, Y, Valdés-Mora, F, Rakotomalala, A, Meignan, S, Pasquier, E, Andre, N, Mannan, Abdul, Hulleman, E, Eisenstat, DD, Vitanza, NA, Nazarian, J, Koschmann, C, Mueller, S, Cain, JE, Dun, MD, Yadavilli, Sridevi, Parackal, Sarah, Game, Shaye, Chong, Wai Chin, Jayasekara, W. Samantha N.